Literature DB >> 18308417

Gallstone disease: from genes to evidence-based therapy.

Frank Lammert1, Juan-Francisco Miquel.   

Abstract

The number of gallstone patients is increasing in ageing populations with a high prevalence of metabolic syndrome and obesity. Recently variants of hepatic ATP binding cassette transporters have been identified as genetic susceptibility factors for gallstone disease, pointing to novel means for risk assessment and prevention. Although laparoscopic cholecystectomy is the mainstay of therapy for symptomatic gallbladder stones, the clinical management of gallstone disease is changing rapidly, with an increase in day case surgery and the advent of transluminal endoscopic surgery. Here, we summarize the molecular and genetic mechanisms of gallstone formation as well as the current evidence-based algorithms for diagnosis and therapy of gallbladder and bile duct stones.

Entities:  

Mesh:

Year:  2008        PMID: 18308417     DOI: 10.1016/j.jhep.2008.01.012

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  21 in total

Review 1.  Targets for current pharmacologic therapy in cholesterol gallstone disease.

Authors:  Agostino Di Ciaula; David Q H Wang; Helen H Wang; Leonilde Bonfrate; Piero Portincasa
Journal:  Gastroenterol Clin North Am       Date:  2010-06       Impact factor: 3.806

2.  Niemann-Pick C2 protein expression regulates lithogenic diet-induced gallstone formation and dietary cholesterol metabolism in mice.

Authors:  Elisa Balboa; Gabriela Morales; Paula Aylwin; Gonzalo Carrasco; Ludwig Amigo; Juan Castro; Attilio Rigotti; Silvana Zanlungo
Journal:  Lipids       Date:  2011-10-30       Impact factor: 1.880

3.  Depletion of hepatic forkhead box O1 does not affect cholelithiasis in male and female mice.

Authors:  Xiaoyun Feng; Cuiling Zhu; Sojin Lee; Jingyang Gao; Ping Zhu; Jun Yamauchi; Chenglin Pan; Sucha Singh; Shen Qu; Rita Miller; Satdarshan P Monga; Yongde Peng; H Henry Dong
Journal:  J Biol Chem       Date:  2020-04-09       Impact factor: 5.157

Review 4.  The Role of Diet in the Pathogenesis of Cholesterol Gallstones.

Authors:  Agostino Di Ciaula; Gabriella Garruti; Gema Frühbeck; Maria De Angelis; Ornella de Bari; David Q-H Wang; Frank Lammert; Piero Portincasa
Journal:  Curr Med Chem       Date:  2019       Impact factor: 4.530

5.  Effect of ezetimibe on the prevalence of cholelithiasis.

Authors:  Assaf Stein; Doron Hermoni; Avishay Elis; Fred M Konikoff
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

Review 6.  Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed.

Authors:  Michele Pier Luca Guarino; Silvia Cocca; Annamaria Altomare; Sara Emerenziani; Michele Cicala
Journal:  World J Gastroenterol       Date:  2013-08-21       Impact factor: 5.742

7.  Recurrence of gallstones after cholecystectomy is associated with ABCG5/8 genotype.

Authors:  Witigo von Schönfels; Stephan Buch; Maren Wölk; Heiko Aselmann; Jan H Egberts; Stefan Schreiber; Michael Krawczak; Thomas Becker; Jochen Hampe; Clemens Schafmayer
Journal:  J Gastroenterol       Date:  2012-08-07       Impact factor: 7.527

8.  Therapy of gallstone disease: What it was, what it is, what it will be.

Authors:  Piero Portincasa; Agostino Di Ciaula; Leonilde Bonfrate; David Qh Wang
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-04-06

Review 9.  Risk Factors for Cholelithiasis.

Authors:  Mila Pak; Glenda Lindseth
Journal:  Gastroenterol Nurs       Date:  2016 Jul-Aug       Impact factor: 0.978

10.  Oblique bile duct predisposes to the recurrence of bile duct stones.

Authors:  Pavel Strnad; Guido von Figura; Regina Gruss; Katja-Marlen Jareis; Adolf Stiehl; Hasan Kulaksiz
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.